The Investment Decision Council concludes that Bristol-Myers Squibb (BMY) is a high-quality, cash-generative pharmaceutical franchise with a durable but maintenance-intensive moat. The business produces roughly $15 B in annual operating cash flow on $48 B revenue, supported by gross margins exceeding 70%. However, recurring impairments (2020 and 2024) and equity shrinkage reveal capital allocation weaknesses. The moat—anchored in patents, regulatory exclusivity, and physician trust—is real but time-bound, requiring continual R&D reinvestment to sustain. Normalized ROIC of 10–12% modestly exceeds the 7–8% cost of capital, implying limited incremental value creation. The council agrees the company’s economics are solid yet not “inevitable.” Buffett and Munger classify it as a good business at a fair price, not a wonderful business at a wonderful price. At $54.28, valuation is near fair value ($60–65 intrinsic), offering only 11–17% margin of safety—below Buffett’s 30% threshold. The dividend yield (4.6%) and low beta (0.30) provide defensive appeal, but patent cliffs (Revlimid, Eliquis) and rising debt ($49.6 B) temper enthusiasm. Consensus stance: Hold, accumulate only if price falls below $45. The council expects 7–9% annual total return over 5 years, primarily from dividends and modest appreciation.